Nir Barzilai

Nir Barzilai directs the Institute for Aging Research at Albert Einstein College of Medicine and holds the Ingeborg and Ira Leon Rennert Chair in Aging Research there [1]. He has published more than 230 peer-reviewed papers and leads the SuperAgers Family Study, an ongoing cohort study of centenarians and their families conducted with the American Federation for Aging Research (AFAR) to find genetic and biological features associated with exceptional human longevity [1].

Barzilai conceived the TAME (Targeting Aging with Metformin) trial, a proposed large-scale randomized controlled trial designed to test whether metformin, a decades-old generic diabetes drug, can delay the onset of a composite of age-related diseases, including heart disease, cancer, and dementia, in nondiabetic older adults [3]. The trial's core scientific rationale rests on observational data suggesting diabetic patients on metformin sometimes have lower rates of some age-related conditions than nondiabetic peers, though establishing causation requires the prospective trial that TAME is designed to be [3]. As of the most recent public reporting, TAME has faced a long and difficult path to full funding, illustrating a structural problem in aging research: the FDA does not currently recognize aging itself as a treatable indication, which complicates trial funding and drug approval pathways for compounds like metformin studied specifically for anti-aging effects [3].

Barzilai holds several commercial roles alongside his academic position. He founded and serves as a director of CohBar Inc., a publicly traded biotech company developing mitochondrial-derived peptide therapeutics, an area of drug development distinct from but adjacent to his aging research [1]. In a more direct overlap with figures already covered in this reference, Barzilai was named Chief Medical Advisor of Life Biosciences, a company co-founded by David Sinclair that is developing partial cellular reprogramming therapies for age-related diseases, according to a BioSpace press release announcing the appointment [2]. This places Barzilai in an advisory relationship with a commercial reprogramming venture whose scientific claims and funding structure are themselves subject to the same kind of scrutiny applied elsewhere on this wiki to Sinclair's other ventures.

Barzilai also serves as President of the Global Academy for Health and Lifespan Research and helps lead the FAST initiative, a joint effort between AFAR and the Advanced Research Projects Agency for Health (ARPA-H) intended to accelerate geroscience-based interventions toward clinical application [1]. These roles are largely nonprofit and grant-coordination functions rather than direct equity positions, distinguishing them from his CohBar and Life Biosciences commercial roles.

On the specific claim that metformin extends healthy lifespan in humans, Barzilai's own public position is more measured than headlines about the drug sometimes suggest: he has consistently framed TAME as the trial needed to establish the effect, rather than treating the underlying hypothesis as already proven, and the trial's slow funding trajectory reflects genuine scientific and regulatory hurdles rather than a settled result awaiting confirmation.

The plain takeaway: Barzilai is one of the most credentialed advocates for treating aging itself as a drug target, and the TAME trial he designed remains scientifically well-regarded even though it has struggled for years to secure full funding, but his simultaneous advisory role at Sinclair's Life Biosciences and directorship at CohBar mean his commercial interests extend well beyond metformin into the broader reprogramming and peptide-therapeutics space.